GSK Plc - ADR
GSK
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 29, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
110.7% upsideUndervalued by 110.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $101.64 Billion |
|---|---|
| Enterprise Value | $122.79 Billion |
| Dividend Yield | $1.80 (3.56%) |
| Earnings per Share | $5.64 |
| Beta | 0.3 |
| Outstanding Shares | 2,011,500,000 |
Return
| Return on Equity | 69.71% |
|---|---|
| Return on Assets | 19.79% |
| Return on Invested Capital | 34.51% |
Valuation & Multiples
| P/E Ratio | 12.99 |
|---|---|
| PEG | 186.62 |
| Price to Sales | 0.35 |
| Price to Book Ratio | 4.66 |
| Enterprise Value to Revenue | 0.41 |
| Enterprise Value to EBIT | 6.67 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 1.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5521▲ 18.40% |
|---|---|
| Total Calls | 3,274,100▼ 28.34% |
| Total Puts | 1,807,740▲ 7.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.62%▼ 1.17% |
|---|---|
| Total Invested | $20.65B▲ 5.86% |
| Investors Holding | 1,051▲ 37.00% |
ESG Score
No data
About Glaxosmithkline plc
CEO: Emma Walmsley Relevant Senate Committees
Although an advisory body, its analysis and revenue estimates are foundational for tax legislation, directly influencing corporate tax policy and the overall tax burden on a multinational company like GSK.
This committee's control over taxation, international trade, and major entitlement programs like Medicare and Medicaid directly impacts GSK's profitability, global supply chain, and primary US revenue streams.
This committee directly controls the funding for federal agencies like the FDA and NIH, and for major healthcare programs (Medicare, Medicaid, VA) which are significant regulators, R&D partners, and customers for GSK.
This committee directly regulates the FDA and NIH, which are critical to GSK's drug approval processes, R&D funding, and overall pharmaceutical market access and operations.
This committee's oversight of intellectual property (patents) and antitrust enforcement directly impacts GSK's core business model, R&D profitability, and potential M&A activities.
The VA is a major purchaser of pharmaceuticals, so the committee's funding decisions directly impact GSK's sales to the federal government healthcare system.